Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas

HER2 testing in gastric cancer: a practical approach

(2012) Josef Rüschoff et al.   MODERN PATHOLOGY

Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas

(2012) Eun Yoon Cho et al.   PATHOLOGY

Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

(2011) Min A Kim et al.   HISTOPATHOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Targeted HER2 Treatment in Advanced Gastric Cancer

(2010) Jan Trøst Jørgensen   ONCOLOGY

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

(2010) Josef Rüschoff et al.   VIRCHOWS ARCHIV

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

(2009) J D Barros-Silva et al.   BRITISH JOURNAL OF CANCER

HER-2 amplification is highly homogenous in gastric cancer

(2009) Andreas H. Marx et al.   HUMAN PATHOLOGY

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

(2009) Guan Zhen Yu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer

(2009) Xiu Li Zhang et al.   WORLD JOURNAL OF SURGERY

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY